Authors

  • Турсунов М.М., Мусашайхова Ш.М., Салохиддинов З.С.

Keywords:

неалкогольная жировая болезнь печени; фиброз печени; полиморфизм C>T; ген IL28B; интерферон-λ3; генетическая предрасположенность; иммуновоспалительные механизмы; прогностический маркер; молекулярно-генетическое исследование.

References

Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. – 2016. – Vol. 64, No. 1. – P. 73–84.

Estes C., Razavi H., Loomba R., Younossi Z., Sanyal A.J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in disease burden // Journal of Hepatology. – 2018. – Vol. 67, No. 1. – P. 123–133.

Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., Harrison S.A., Brunt E.M., Sanyal A.J. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the AASLD // Hepatology. – 2018. – Vol. 67, No. 1. – P. 328–357.

Byrne C.D., Targher G. NAFLD: a multisystem disease // The Lancet. – 2015. – Vol. 386, No. 9991. – P. 1341–1351.

Loomba R., Sanyal A.J. The global NAFLD epidemic // Nature Reviews Gastroenterology & Hepatology. – 2013. – Vol. 10, No. 11. – P. 686–690.

Angulo P. Nonalcoholic fatty liver disease and liver fibrosis // Gastroenterology. – 2007. – Vol. 132, No. 4. – P. 1797–1811.

Friedman S.L. Hepatic fibrosis: emerging mechanisms and therapies // Nature Reviews Gastroenterology & Hepatology. – 2018. – Vol. 15, No. 11. – P. 667–685.

Dulai P.S., Singh S., Patel J., Soni M., Prokop L.J., Younossi Z., Sebastiani G., Ekstedt M., Hagström H., Nasr P., et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis // Hepatology. – 2017. – Vol. 65, No. 5. – P. 1557–1565.

Ekstedt M., Hagström H., Nasr P., Fredrikson M., Stål P., Kechagias S., Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD // Hepatology. – 2015. – Vol. 61, No. 5. – P. 1547–1554.

Pais R., Charlotte F., Fedchuk L., Bedossa P., Lebray P., Poynard T., Ratziu V. A systematic review of follow-up biopsies reveals disease progression in NAFLD // Clinical Research in Hepatology and Gastroenterology. – 2016. – Vol. 37, No. 4. – P. 406–414.

McPherson S., Hardy T., Henderson E., Burt A.D., Day C.P., Anstee Q.M. Evidence of NAFLD fibrosis progression from paired liver biopsies // Gut. – 2015. – Vol. 64, No. 11. – P. 1896–1905.

Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis // Gut. – 2010. – Vol. 59, No. 4. – P. 563–572.

Buzzetti E., Pinzani M., Tsochatzis E.A. The multiple-hit pathogenesis of nonalcoholic fatty liver disease // Metabolism. – 2016. – Vol. 65, No. 8. – P. 1038–1048.

Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., Langer J.A., Sheikh F., Dickensheets H., Donnelly R.P. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex // Nature Immunology. – 2003. – Vol. 4, No. 1. – P. 69–77.

Lazear H.M., Schoggins J.W., Diamond M.S. Shared and distinct functions of type I and type III interferons // Immunity. – 2019. – Vol. 50, No. 4. – P. 907–923.

Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance // Nature. – 2009. – Vol. 461, No. 7262. – P. 399–401.

Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O’Huigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus // Nature. – 2009. – Vol. 461, No. 7265. – P. 798–801.

Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure // Hepatology. – 2010. – Vol. 51, No. 4. – P. 1091–1099.

Seki E., Brenner D.A. Recent advancement of molecular mechanisms of liver fibrosis // Journal of Clinical Investigation. – 2015. – Vol. 125, No. 1. – P. 55–64.

Tacke F., Zimmermann H.W. Macrophage heterogeneity in liver injury and fibrosis // Journal of Hepatology. – 2014. – Vol. 60, No. 5. – P. 1090–1096.

Petta S., Valenti L., Bugianesi E., Targher G., Bellentani S., Bonino F. A “systems medicine” approach to NAFLD // Journal of Hepatology. – 2016. – Vol. 65, No. 2. – P. 389–398.

Eslam M., Valenti L., Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact // Journal of Hepatology. – 2018. – Vol. 68, No. 2. – P. 268–279.

Sookoian S., Pirola C.J. Genetic predisposition in nonalcoholic fatty liver disease // Clinical Liver Disease. – 2018. – Vol. 22, No. 1. – P. 59–73.

Targher G., Byrne C.D., Lonardo A., Zoppini G., Barbui C. Nonalcoholic fatty liver disease and risk of cardiovascular disease // Diabetologia. – 2016. – Vol. 59, No. 6. – P. 1111–1120.

Day C.P. Pathogenesis of steatohepatitis // Best Practice & Research Clinical Gastroenterology. – 2011. – Vol. 25, No. 2. – P. 291–301.

Bedossa P. Histological assessment of nonalcoholic fatty liver disease // Seminars in Liver Disease. – 2015. – Vol. 35, No. 2. – P. 132–140.

Anstee Q.M., Day C.P. The genetics of nonalcoholic fatty liver disease // Nature Reviews Gastroenterology & Hepatology. – 2017. – Vol. 14, No. 10. – P. 645–657.

Eslam M., George J. Genomics of nonalcoholic fatty liver disease // Seminars in Liver Disease. – 2019. – Vol. 39, No. 1. – P. 1–11.

Tilg H., Adolph T.E., Dudek M., Knolle P. Immune dysregulation in nonalcoholic fatty liver disease // Hepatology. – 2021. – Vol. 73, No. 5. – P. 1723–1735.

Loomba R., Schork N., Chen C.H., Bettencourt R., Bhatt A., Ang B., Nguyen P., Hernandez C., Richards L., Salotti J., et al. Precision medicine in NAFLD // Nature Reviews Gastroenterology & Hepatology. – 2021. – Vol. 18, No. 8. – P. 541–552.